Clinical trials: Hypertensive Disease
Glaucoma
Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Glaucoma
The purpose of this study is to assess patient preference of AZARGA® compared to COSOPT® after a single drop of each medication is administered to both eyes, in patients with open-angled glaucoma or ocular hypertension.
- Trial name
- NCT01471158
- Testing
- Brinzolamide/Timolol Maleate Fixed Combination (AZARGA), Dorzolamide/timolol Maleate Fixed Combination (COSOPT)
- Where
- Argentina
- Volunteers
- 120 people
- Sponsor
- Alcon Research
Hypertension
A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure
Carvedilol controlled release is a marketed drug to treat high blood pressure. This study is to compare carvedilol controlled release to carvedilol controlled release plus lisinopril (fixed-dose combination) after repeat dosing…
- Trial name
- NCT00537043
- Testing
- SK&F-105517 (COREG CR FDC)
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Insulin Resistance, Obesity
Pilot Study of GLY-LOW Supplementation in Postmenopausal Women With Obesity
A combination of generally regarded as safe (GRAS) compounds named GLY-LOW, which included: alpha lipoic acid, pyridoxamine, nicotinamide, piperine and thiamine, were examined in pre-clinical experiments.
- Conditions
- Insulin Resistance, Obesity, Cardiovascular Diseases, Cognitive Impairment
- Trial name
- NCT06242535
- Testing
- GLY-LOW
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Hoskinson Health and Wellness Clinic
Hypertension, Pulmonary
Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529
An open label, long term extension to Study AMB112529. All subjects may remain in the extension study for a minimum of six months.
- Trial name
- NCT01342952
- Testing
- Ambrisentan
- Where
- 22 sites in United States, Argentina and 7 more
- Volunteers
- 38 people
- Sponsor
- GlaxoSmithKline
Hypertension
A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults
The purpose of this study was to assess the pharmacokinetics (PK) and safety of a single dose of azilsartan medoxomil in children with hypertension, and comparative PK in healthy adults.
- Trial name
- NCT01078376
- Testing
- Azilsartan medoxomil (TAK-491)
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Takeda
Hypertension
Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)
Blood pressure in hypertensive patients is rarely controlled to an optimal level by one drug alone, often a combination of two or more drugs is essential to achieve a sufficient antihypertensive effect.
- Trial name
- NCT01286558
- Testing
- 40 mg telmisartan, 5 mg amlodipine, 80 mg telmisartan
- Where
- 8 sites in Japan
- Volunteers
- 225 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - A
The purpose of this study is to compare the safety and pharmacokinetics of CKD-330 (fixed-dose combination of Candesartan 16 mg and Amlodipine 5 mg) with coadministration of the two separate drugs in healthy male volunteers.
- Trial name
- NCT02801526
- Testing
- CKD-330 16/5mg - A, Candesartan 16mg and Amlodipine 5mg
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Pulmonary Hypertension
Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
This study is an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who are currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or…
- Trial name
- FREEDOM-C2 (NCT00887978)
- Testing
- UT-15C SR
- Where
- 62 sites in United States, Belgium and 10 more
- Volunteers
- 310 people
- Sponsor
- United Therapeutics
Viral Hepatitis B, Viral Hepatitis D
Replicor Compassionate Access Program
The goal of this compassionate access program is to provide early access to REP 2139-Mg for patients with HBV mono-infection or HBV / HDV co-infection who either have advanced (decompensated) cirrhosis or who have failed to…
- Conditions
- Viral Hepatitis B, Viral Hepatitis D, Cirrhosis, Liver, Decompensated Cirrhosis
- Trial name
- RCAP (NCT05683548)
- Testing
- REP 2139-Mg, Tenofovir Disoproxil Fumarate, Pegylated interferon alpha2a
- Where
- 13 sites in Austria, France and 3 more
- Sponsor
- Replicor Inc.
Glaucoma, Ocular Hypertension
A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
This safety study will evaluate bimatoprost 0.01% and 0.03% in patients with glaucoma or ocular hypertension (OHT).
- Trial name
- NCT01830140
- Testing
- Bimatoprost 0.01%, Bimatoprost 0.03%
- Where
- 2 sites in United States
- Volunteers
- 466 people
- Sponsor
- Allergan
Hypertension
An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination
To assess the long term safety and efficacy of telmisartan plus amlodipine FDC in patients with essential hypertension who failed to control their BP with either monotherapy
- Trial name
- NCT00618774
- Testing
- telmisartan40/amlodipine5, telmisartan80/amlodipine5
- Where
- 7 sites in Japan
- Volunteers
- 259 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Arterial Hypertension
Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH
This is a multicenter, single-arm trial to evaluate the safety of the transition from Selexipag to Remodulin® then Oral Treprostinil in Symptomatic Subjects with Pulmonary Arterial Hypertension (PAH).
- Trial name
- NCT03016468
- Testing
- Parenteral Remodulin (treprostinil) injection, Oral Treprostinil
- Sponsor
- United Therapeutics
Hypertension
Safety and Efficacy of MK0736 & MK0916 in Patients With Hypertension (High Blood Pressure)(0736-003)(COMPLETED)
The objective of this study is to evaluate the safety and efficacy of two investigational drugs (MK-0736 and MK-0916) in lowering blood pressure and body weight in patients with hypertension (high blood pressure).
- Trial name
- NCT00274716
- Testing
- MK0736, MK0916
- Volunteers
- 249 people
- Sponsor
- Merck Sharp & Dohme LLC
Glaucoma
The Minimally Invasive Micro Sclerostomy (MIMS®) System is Intended for the Reduction of Elevated Intraocular Pressure (IOP): The Minimally Invasive Micro Sclerostomy (MIMS®) System is Intended for the Reduction of Elevated Intraocular Pressure (IOP)
No new investigational device is used in this study. This study is an extension follow up study conducted in continuation of the prior MIMS® study (see: STUDY ID: MMS EEU-1), in which the long-term (i.e., 28, 36, 42 months)…
- Trial name
- NCT07051174
- Testing
- MIMS
- Where
- Armenia
- Volunteers
- 88 people
- Sponsor
- Sanoculis Ltd
Hypertension
Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension
The purpose of the study is to evaluate the blood pressure lowering effect and safety of aliskiren in combination with Hydrochlorothiazide (HCTZ) compared to aliskiren monotherapy when given to metabolic syndrome patients with…
- Trial name
- AIMS (NCT00797316)
- Testing
- Aliskiren, Hydrochlorothiazide
- Where
- United States
- Volunteers
- 532 people
- Sponsor
- Novartis
Hypertension
Pharmacokinetics of BIBR 277 in Hypertensive Patients
The pharmacokinetic profile of BIBR 277 single dose given in capsule form to hypertensives was evaluated. The results of the present study are to be used in the Japanese population pharmacokinetics analysis
- Trial name
- NCT02187497
- Testing
- Low dose of BIBR 277, Medium dose of BIBR 277, High dose of BIBR 277
- Volunteers
- 93 people
- Sponsor
- Boehringer Ingelheim
Hypertension
A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension
A multicenter, randomized, double-blind, parallel, phase 2 study to assess dose-response relationship of HCP1803 in patients with essential hypertension
- Trial name
- HM_APOLLO (NCT03897868)
- Testing
- HCP1803, Amlodipine, Losartan
- Where
- South Korea
- Volunteers
- 248 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Pulmonary Arterial Hypertension
Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus background pulmonary arterial hypertension [PAH] therapy) versus placebo (plus background PAH therapy) on…
- Trial name
- HYPERION (NCT04811092)
- Testing
- Sotatercept
- Where
- 152 sites in United States, Argentina and 25 more
- Volunteers
- 321 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Hypertension, Congestive Heart Failure
To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure
To compare and evaluate the efficacy and safety of Candemore tab. versus Atacand tab. on blood pressure in patients with hypertension diagnosed congestive heart failure
- Trial name
- CANTABILE (NCT01682564)
- Testing
- Candemore tablet, Atacand tablet
- Where
- 14 sites in South Korea
- Volunteers
- 169 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension With Renal Dysfunction
Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction
This study assessed the safety, tolerability, and efficacy of LCZ696 in hypertensive patients with renal dysfunction.
- Trial name
- NCT01593787
- Testing
- LCZ696
- Where
- 13 sites in Japan
- Volunteers
- 32 people
- Sponsor
- Novartis Pharmaceuticals